Amicus Therapeutics (NASDAQ: FOLD) reported Q1 EPS of ($0.39), $0.03 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $4.16 million.

• 100+ Fabry Disease Patients Now on Reimbursed Galafold (migalastat) in the EU
• On Target to Reach 300 Patients on Galafold by Year-End 2017
• Additional Important Phase 1/2 Pompe Clinical Data Expected in 2Q17 and 3Q17
• Phase 3 EB Topline Data on Track for 3Q17

2017 Financial Guidance

Cash, cash equivalents, and marketable securities totaled $279.8 million at March 31, 2017. The Company continues to expect full-year 2017 net operating cash spend of between $175 million to $200 million and full-year 2017 total net cash spend (including third-party milestone payments and capital expenditures) of between $200 million and $225 million. The current cash position is anticipated to fund ongoing operations into the second half of 2018.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.